Pharvaris Announces Annual Meeting of Shareholders
June 11, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
June 04, 2024 06:50 ET
|
Pharvaris N.V.
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hoursHigh treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score...
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
May 13, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:10 ET
|
Pharvaris N.V.
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant...
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 10, 2024 16:10 ET
|
Pharvaris N.V.
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of...
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
April 10, 2024 16:08 ET
|
Pharvaris N.V.
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
April 04, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
March 18, 2024 06:50 ET
|
Pharvaris N.V.
The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks ...
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
March 06, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
March 05, 2024 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary...